SPOTLIGHT: Allergan to pay $370M for Esprit Pharma


Allergan has inked a deal to buy privately held Esprit Pharma, which specializes in genitourinary treatments, for $370 million. Esprit currently markets Sanctura, a remedy for overactive bladder, and has applied for FDA approval for an extended release form of that drug. Release

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?